Tue, March 4, 2025
Mon, March 3, 2025
Sun, March 2, 2025
Sat, March 1, 2025
Fri, February 28, 2025
Sun, February 23, 2025
Sat, February 22, 2025
Fri, February 21, 2025
[ Fri, Feb 21st ] - Wired
The Ozempic Shortage Is Over
Thu, February 20, 2025
Wed, February 19, 2025
Tue, February 18, 2025
[ Tue, Feb 18th ] - Politico
Culling the AI workforce
Mon, February 17, 2025

NICE green lights two blood cancer therapies for NHS use


//science-technology.news-articles.net/content/2 .. ghts-two-blood-cancer-therapies-for-nhs-use.html
Published in Science and Technology on by MSN   Print publication without navigation

BMS' Breyanzi and Amgen's Blincyto will now be available to patients in England with certain types of blood cancer.

The UK's National Institute for Health and Care Excellence (NICE) has approved two new therapies, mosunetuzumab (Lunsumio) and glofitamab (Columvi), for treating specific types of blood cancer within the NHS. These treatments are targeted at adults with relapsed or refractory follicular lymphoma (FL) who have undergone at least two prior lines of systemic therapy. Mosunetuzumab is administered as a fixed course over 8 cycles, while glofitamab is given until disease progression or unacceptable toxicity. Both drugs work by engaging the body's immune system to attack cancer cells, offering a new hope for patients with this aggressive form of lymphoma. The approval follows a recommendation from NICE's Highly Specialised Technologies committee, highlighting the potential of these therapies to significantly improve patient outcomes.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/science/biology/nice-green-lights-two-blood-cancer-therapies-for-nhs-use/ar-AA1zxweQ ]

Publication Contributing Sources